Navigation Links
MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
Date:3/14/2013

KENNESAW, Ga., March 14, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the Canaccord Genuity Musculoskeletal Conference in Chicago.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor , President and COO, and Michael J. Senken , Chief Financial Officer, are scheduled to present on March 19th at 3:20 p.m. CDT/4:20 p.m. EDT at the Westin Michigan Avenue.  A webcast of this presentation will be available on the Company's website, www.mimedx.com

About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary Purion® Process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 130,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.


'/>"/>
SOURCE MiMedx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
2. MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results
3. MiMedx Group to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
4. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
5. MiMedx Group to Present at the Craig-Hallum 2012 Alpha Select Conference
6. MiMedx Group to Present at the BIOX; Noble Financial Capital Markets Life Sciences Exposition
7. MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
8. MiMedx Group to Present at the Canaccord Genuity Annual Growth Conference
9. MiMedx Group Announces Record Second Quarter Results
10. MiMedx Group, Inc. Announces Release Date for 2012 Second Quarter Results
11. MiMedx Group Announces Record First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose is a ... and error process by finding the right antidepressant faster. CNSDose speeds recovery ... relationship through a personalized approach to treatment. , A peer-reviewed and ...
(Date:5/18/2017)... Mass. (PRWEB) , ... May 18, 2017 , ... ... the procedure on April 28, 2017 at the Prince Of Wales Private Hospital. ... cervical disc at level C6-C7. The patient failed conservative treatments prior to undergoing ...
(Date:5/18/2017)... ... May 17, 2017 , ... NDA Partners Chairman Carl Peck, MD , ... Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal Health, has joined ... Cardinal Health, he was former Chief Operating Officer at Anaborex, Senior VP and General ...
(Date:5/18/2017)... ... May 17, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, is honored that Jay Crowley ... conference in Brussels, Belgium. , Crowley played a crucial role in the development ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):